Use of natriuretic peptide for treating heart failure
AssigneeCardiopep Pharma GmbH
InventorsVeselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
Claims28
A method for treating acute decompensated heart failure (ADHF) or decompensated heart failure (DHF) in a patient, comprising administering continuously for a time period of at least 24 hours to the patient, a composition comprising an effective amount of urodilatin, wherein the patient exhibits improvement in an ADHF or DHF related parameter which is pulmonary capillary wedge pressure and the patient exhibits improvement in ADHF or DHF related dyspnea.
Dependencies are inferred from the claim text.